OPA1 and autosomal dominant optic atrophy: Whilst it is not currently feasible to create individual gene editing strategies individually for the >500 pathogenic OPA1 variants known to cause ADOA, this technique could be helpful for drug screening and the development of optic nerve regeneration strategies [66].